Literature DB >> 24131971

Local approaches to hereditary breast cancer.

B T Cooper1, J O Murphy, V Sacchini, S C Formenti.   

Abstract

The diagnostic and local treatment modalities of hereditary breast cancer (HBC) are evolving based on emerging evidence from new imaging, radiotherapy and surgical studies. The optimal selection of diagnostic and therapeutic strategies for the individual HBC patient remains an area of active research in this relatively new patient population. In this context, some rational pathways of intervention are currently available to both reduce cancer risk in mutation carriers without a cancer diagnosis, as well as to reduce the risk of recurrence or new cancers among the carriers already diagnosed with a malignancy. It is encouraging to notice to what degree certain interventions have successfully reduced both the risk of malignancy and the anxiety associated with this genetic diagnosis. This updated report aims at summarizing the most recent findings, while it identifies the areas of uncertainty that remain, and continue to present difficult challenges, particularly among younger HBC patients.

Entities:  

Keywords:  BRCA1; BRCA2; hereditary breast cancer; radiation; radiation-induced malignancy

Mesh:

Substances:

Year:  2013        PMID: 24131971     DOI: 10.1093/annonc/mdt327

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  3 in total

1.  Dose-response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial.

Authors:  Kathryn H Schmitz; Nancy I Williams; Despina Kontos; Susan Domchek; Knashawn H Morales; Wei-Ting Hwang; Lorita L Grant; Laura DiGiovanni; Domenick Salvatore; Desire' Fenderson; Mitchell Schnall; Mary Lou Galantino; Jill Stopfer; Mindy S Kurzer; Shandong Wu; Jessica Adelman; Justin C Brown; Jerene Good
Journal:  Breast Cancer Res Treat       Date:  2015-10-28       Impact factor: 4.872

Review 2.  Risk-reducing mastectomy.

Authors:  Federica Chiesa; Virgilio S Sacchini
Journal:  Minerva Ginecol       Date:  2016-01-19

3.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.